PKAN pathogenesis and treatment
PKAN pathogenesis and treatment
批准号:
10023954
负责人:
SUSAN J HAYFLICK
金额:
$33.69万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-30 至 2022-08-31
关键词:
4&apos-phosphopantetheineAcyl Carrier ProteinAdultAgeBiochemical ReactionBiogenesisBiological MarkersBlindnessBrainBrain regionCarrier ProteinsCell LineCell physiologyCellsCessation of lifeChildCoenzyme AComplexConsumptionDataDefectDevelopmentDiseaseDisease modelDopamineDystoniaElementsFatty AcidsFunctional disorderGenderGene ExpressionGenesGeneticGenetic DiseasesGoalsHallervorden-Spatz SyndromeHereditary DiseaseHomeostasisHumanIntervention TrialIronIsoenzymesKnockout MiceKnowledgeLeukocytesLinkMammalsMediatingMendelian disorderMetabolicMetabolismMitochondriaMitochondrial ProteinsModelingMolecularMolecular ProfilingMusMutant Strains MiceNerve DegenerationNeurodegenerative DisordersOralOxidative PhosphorylationPainPantothenate kinaseParkinsonian DisordersPathogenesisPathway interactionsPhenotypeProcessProsthesisReactionResearchResourcesRoleRotenoneSourceSulfurSurrogate MarkersSystemTestingTherapeuticTranslatingTreatment Efficacybrain abnormalitiesburden of illnessdopaminergic neurongene repressionimprovedinsightmouse modelneurotransmissionnovel strategiestherapeutic candidatetherapeutic evaluationtool
中文摘要
项目总结/摘要
单基因疾病为常见疾病的机制提供了有价值的见解,并代表了高度
开发合理疗法的易处理系统。泛酸激酶相关
神经变性)是一种严重致残和痛苦的遗传性疾病,引起肌张力障碍,帕金森症,
儿童和成人的失明和早逝。目前还没有疾病修饰治疗。我们
长期目标是阐明发病机理并开发这种致命疾病的治疗方法。
PKAN是辅酶A(CoA)合成的先天性错误,导致脑铁神经变性
积累虽然脑铁积累是PKAN的一个标志,但缺陷CoA与PKAN之间的联系可能是一个潜在的联系。
铁代谢、铁稳态异常和神经变性仍不清楚。
缺乏一个强大的哺乳动物疾病模型的PKAN限制了研究进展,仍然代表了一个新的研究领域。
该领域的关键研究资源。使用小鼠敲除Pank 2和一种新的分离方法
我们发现了一组与疾病相关的大脑区域,
异常这种分子“特征”包括辅酶A、铁和多巴胺代谢紊乱的标志物
氧化磷酸化只在易患病的区域。我们建议调查这个强大的
该模型的目标是描述PKAN的分子发病机制,以证明候选药物的有效性,
治疗,并发现可用于人类干预试验的生物标志物。
英文摘要
PROJECT SUMMARY/ABSTRACT
Single gene disorders provide valuable insights into mechanisms of common diseases and represent highly
tractable systems for developing rational therapeutics. PKAN (pantothenate kinase-associated
neurodegeneration) is a profoundly disabling and painful genetic disorder causing dystonia, parkinsonism,
blindness and early death in children and adults. Currently there are no disease-modifying treatments. Our
long-term goals are to elucidate pathogenesis and develop a treatment for this lethal disease.
PKAN is an inborn error of coenzyme A (CoA) synthesis that results in neurodegeneration with brain iron
accumulation. Though brain iron accumulation is a hallmark of PKAN, the link between defective CoA
metabolism, iron dyshomeostasis, and neurodegeneration has remained unclear.
The lack of a robust mammalian disease model of PKAN has limited research progress and still represents a
critical research resource for the field. Using a mouse knock-out of Pank2 and a new approach to separating
disease-vulnerable from disease-protected brain regions, we have discovered a set of disease-relevant brain
abnormalities. This molecular `signature' includes markers of perturbed CoA, iron, and dopamine metabolism
and oxidative phosphorylation only in the disease-vulnerable regions. We propose to investigate this powerful
model with the goals to delineate the molecular pathogenesis of PKAN, to demonstrate efficacy of a candidate
therapeutic, and to discover biomarkers that can be translated for use in human interventional trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PKAN pathogenesis and treatment
-
批准号:9788120
-
项目类别:
-
资助金额:$33.69万
-
财政年份:2018
-
负责人:SUSAN J HAYFLICK
-
依托单位:
Coenzyme A replenishment as a therapeutic strategy for inborn errors of metabolism
-
批准号:9243829
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2017
-
负责人:SUSAN J HAYFLICK
-
依托单位:
The Molecular Basis of Infantile Neuroaxonal Dystrophy
-
批准号:7105884
-
项目类别:
-
资助金额:$26.43万
-
财政年份:2006
-
负责人:SUSAN J HAYFLICK
-
依托单位:
The Molecular Basis of Infantile Neuroaxonal Dystrophy
-
批准号:7348430
-
项目类别:
-
资助金额:$25.65万
-
财政年份:2006
-
负责人:SUSAN J HAYFLICK
-
依托单位:
The Molecular Basis of Infantile Neuroaxonal Dystrophy
-
批准号:7231385
-
项目类别:
-
资助金额:$26.14万
-
财政年份:2006
-
负责人:SUSAN J HAYFLICK
-
依托单位:
A PILOT STUDY TO DELINEATE BIOCHEMICAL PHENOTYPE AND CLINICAL OUTCOME MEASURES
-
批准号:7206602
-
项目类别:
-
资助金额:$3.92万
-
财政年份:2005
-
负责人:SUSAN J HAYFLICK
-
依托单位:
A Pilot Study to Delineate Biochemical Phenotype and Clinical Outcome Measures
-
批准号:6981135
-
项目类别:
-
资助金额:$4.09万
-
财政年份:2003
-
负责人:SUSAN J HAYFLICK
-
依托单位:
FIRST SCIENTIFIC WORKSHOP ON HALLERVORDEN-SPATZ SYNDROME
-
批准号:6191591
-
项目类别:
-
资助金额:$4.2万
-
财政年份:2000
-
负责人:SUSAN J HAYFLICK
-
依托单位:
Molecular Basis of Syndromic Retinitis Pigmentosa
-
批准号:6727032
-
项目类别:
-
资助金额:$38.26万
-
财政年份:1999
-
负责人:SUSAN J HAYFLICK
-
依托单位:
MOLECULAR BASIS OF SYNDROMIC RETINITIS PIGMENTOSA
-
批准号:6138219
-
项目类别:
-
资助金额:$26.68万
-
财政年份:1999
-
负责人:SUSAN J HAYFLICK
-
依托单位:
The Molecular Basis of Syndromic Retinitis Pigmentosa
-
批准号:6986061
-
项目类别:
-
资助金额:$52.23万
-
财政年份:1999
-
负责人:SUSAN J HAYFLICK
-
依托单位:
MOLECULAR BASIS OF SYNDROMIC RETINITIS PIGMENTOSA
-
批准号:6489844
-
项目类别:
-
资助金额:$49.23万
-
财政年份:1999
-
负责人:SUSAN J HAYFLICK
-
依托单位:
MOLECULAR BASIS OF SYNDROMIC RETINITIS PIGMENTOSA
-
批准号:6342668
-
项目类别:
-
资助金额:$45.63万
-
财政年份:1999
-
负责人:SUSAN J HAYFLICK
-
依托单位:
MOLECULAR BASIS OF SYNDROMIC RETINITIS PIGMENTOSA
-
批准号:6627058
-
项目类别:
-
资助金额:$49.29万
-
财政年份:1999
-
负责人:SUSAN J HAYFLICK
-
依托单位:
MOLECULAR BASIS OF SYNDROMIC RETINITIS PIGMENTOSA
-
批准号:2738392
-
项目类别:
-
资助金额:$24.23万
-
财政年份:1999
-
负责人:SUSAN J HAYFLICK
-
依托单位:
The Molecular Basis of Syndromic Retinitis Pigmentosa
-
批准号:6833965
-
项目类别:
-
资助金额:$37.82万
-
财政年份:1999
-
负责人:SUSAN J HAYFLICK
-
依托单位:
The Molecular Basis of Syndromic Retinitis Pigmentosa
-
批准号:7123306
-
项目类别:
-
资助金额:$3.62万
-
财政年份:1999
-
负责人:SUSAN J HAYFLICK
-
依托单位:
The Molecular Basis of Syndromic Retinitis Pigmentosa
-
批准号:7176090
-
项目类别:
-
资助金额:$38.96万
-
财政年份:1999
-
负责人:SUSAN J HAYFLICK
-
依托单位:
MOLECULAR BASIS OF SYNDROMIC RETINITIS PIGMENTOSA
-
批准号:5200050
-
项目类别:
-
资助金额:$12.71万
-
财政年份:1995
-
负责人:SUSAN J HAYFLICK
-
依托单位:
MOLECULAR BASIS OF SYNDROMIC RETINITIS PIGMENTOSA
-
批准号:2157868
-
项目类别:
-
资助金额:$8.08万
-
财政年份:1995
-
负责人:SUSAN J HAYFLICK
-
依托单位:
海外基金